secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001104659-25-022371
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee Therapeutics enters manufacturing agreement with Samsung Biologics for APG777 drug substance
--------------------------------------------------------------------------------

- Master Services Agreement with Samsung Biologics for manufacture and supply of APG777 drug substance for clinical development and commercial sale if approved.
- Initial Project Specific Agreement for clinical batches, process characterization/validation, and process performance qualification lots at Samsung's Incheon facility.
- Minimum purchase quantities under Initial PSA; commercial supply PSA from 2029-2034 with minimum commitments; exit fee high single digit millions if not entered.
- MSA terminates February 2035; Initial PSA terminates December 2034; termination rights for material breach, insolvency, force majeure.
- Upon termination, Samsung to assist with technology transfer; without-cause termination results in payment for remaining product commitment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465925022371/0001104659-25-022371-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465925022371/tm258743d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-022371

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer